Heterogeneity of T1DM raises questions for therapy (original) (raw)

Type 1 diabetes mellitus in 2011

Nature Reviews Endocrinology volume 8, pages 78–80 (2012)Cite this article

Subjects

Research in 2011 regarding β-cell destruction, early immunointervention trials and development of late complications in type 1 diabetes mellitus have highlighted the heterogeneity of this disease. Patient phenotyping should be performed for the implementation of tailored therapies, especially taking into account the age at which the disease is diagnosed.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Bottino, R. et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 53, 2559–2568 (2004).
    Article CAS PubMed Google Scholar
  2. Tran, P. O et al. Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress. J. Biol. Chem. 279, 53988–53993 (2004).
    Article CAS PubMed Google Scholar
  3. Thayer, T. C, et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes 60, 2144–2151 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  4. Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412–419 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  5. Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487–497 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  6. Klinke, D. J. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS ONE 6, e26873 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  7. Buzzetti, R. et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60, 3067–3072 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  8. Lind, M. et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378, 140–146 (2011).
    Article PubMed Google Scholar
  9. Sun, J. K. et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care 34, 968–974 (2011).
    Article PubMed PubMed Central Google Scholar
  10. Thomas, M. C, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 54, 2669–2677 (2011).
    Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Diabetes, University Campus Bio-Medico, Via Álvaro del Portillo, 21, Rome, 00128, Italy
    Paolo Pozzilli

Authors

  1. Paolo Pozzilli
    You can also search for this author inPubMed Google Scholar

Ethics declarations

Competing interests

The author declares associations with the following companies: Andromeda Biotech (consultant, grant/research support), Bristol-Meyers Squibb (speakers bureau), GlaxoSmithKline (grant/research support, speakers bureau), Novartis (speakers bureau), Sanofi-Aventis (speakers bureau).

Rights and permissions

About this article

Cite this article

Pozzilli, P. Heterogeneity of T1DM raises questions for therapy.Nat Rev Endocrinol 8, 78–80 (2012). https://doi.org/10.1038/nrendo.2011.228

Download citation

This article is cited by